COL17A1. a gene encoding collagen type XVII alpha 1 chain (also known as BP180 or BPAG2), is a transmembrane protein critical for maintaining epidermal-dermal adhesion. As a key component of hemidesmosomes, it stabilizes the basement membrane zone by anchoring epithelial cells to the underlying extracellular matrix. COL17A1 is expressed in basal keratinocytes and plays roles in tissue integrity, wound healing, and stem cell niche regulation. Antibodies targeting COL17A1 are primarily studied in autoimmune blistering disorders, notably bullous pemphigoid (BP) and mucous membrane pemphigoid, where autoantibodies disrupt COL17A1 function, leading to subepidermal blistering. These antibodies are detected via immunofluorescence, ELISA, or immunoblotting in clinical diagnostics. Beyond autoimmune contexts, COL17A1 antibodies are used in research to explore its roles in epithelial-mesenchymal transition, cancer progression, and aging-related tissue degeneration. Mutations in COL17A1 also cause junctional epidermolysis bullosa, a genetic disorder characterized by fragile skin. Recent studies highlight COL17A1's involvement in stem cell maintenance, making its antibodies valuable tools for investigating regenerative mechanisms. Therapeutic strategies targeting COL17A1. such as antibody-blocking agents, are under exploration for autoimmune and degenerative conditions.